Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5% albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic and pancreatic surgery
Purpose The aim of this study was to evaluate the effects of hydroxyethyl starch (HES) 130/0.4/9 compared to 5% albumin on renal and coagulation safety profiles, volume efficacy and glycocalyx degradation in major abdominal surgery. Methods The study was approved by the institutional ethics committe...
Gespeichert in:
| Veröffentlicht in: | Journal of anesthesia 2020-12, Vol.34 (6), p.912-923 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 923 |
|---|---|
| container_issue | 6 |
| container_start_page | 912 |
| container_title | Journal of anesthesia |
| container_volume | 34 |
| creator | Suzuki, Toshinari Koyama, Kaoru |
| description | Purpose
The aim of this study was to evaluate the effects of hydroxyethyl starch (HES) 130/0.4/9 compared to 5% albumin on renal and coagulation safety profiles, volume efficacy and glycocalyx degradation in major abdominal surgery.
Methods
The study was approved by the institutional ethics committee as a single center, open-labeled randomized trial. Fifty patients undergoing hepatic or pancreatic surgery were randomly assigned to the HES group (
n
= 25), who received HES 130/0.4/9, or the Albumin group (
n
= 25), who received 5% albumin. Ringer’s acetate solution (3 ml/kg/h) and colloid solution (2 mL/kg/h) were infused and goal-directed fluid management was performed to stabilize hemodynamics. Perioperative changes and differences in serum creatinine, N-acetyl-beta-d-glucosaminidase (NAG), hemodynamics, coagulation parameters and glycocalyx biomarkers were compared between the groups. Blood loss and requirements for transfusion and vasoactive agents were also examined. Statistical analysis was performed by Mann–Whitney
U
tests, chi-square or Fisher exact test, with
P
|
| doi_str_mv | 10.1007/s00540-020-02847-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2440902081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651154207</galeid><sourcerecordid>A651154207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-12f103d557ffc9dfaa6d6bc87971fe49d1fcd1c918c4b4bc71140446689956d33</originalsourceid><addsrcrecordid>eNp9kl1rHCEUhofS0mzT_oFeFKEEepHZ1dH58DKE9AMCuWmvxdHj7gRHtzoTYn9Zf17cnbRQWIqIHnzeF89HUbwneE0wbjcR45rhEleH3bG2TC-KFWG0Kzta85fFCnNCy65purPiTYz3GOOGEPq6OKNVx1tG21Xx-24PDgXptB-HX6DRFAZpkTdo2gECY0BN8RA2F2iXdPCPCaZdsihOMqgdIhRv8JptOMoWqL5A0vbzODjkHYrSwJTQPngzWLhED97O49F0UFKly6Nka5PyStr0iDRsg9RyGrI2O-xgn-_qSO2lUwGOYZzDFkJ6W7wy0kZ493yeFz8-33y__lre3n35dn11W6q64VNJKkMw1XXdGqO4NlI2uulV1_KWGGBcE6M0UZx0ivWsVy0hDDOWa8Z53WhKz4tPi29O4-cMcRLjEBVYKx34OYqKMcxzCzqS0Y8LupUWxOCMn4JUB1xcNTUhNatwm6nyBLUFB0Fa7-BQq3_59Qk-Lw3joE4KqkWggo8xgBH7MIwyJEGwOAyOWAZH5F-L4-CIlEUfntOc-xH0X8mfSckAXYCYn1zugLj3c3C59P-zfQLYQs4x</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440902081</pqid></control><display><type>article</type><title>Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5% albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic and pancreatic surgery</title><source>MEDLINE</source><source>Springer Journals</source><creator>Suzuki, Toshinari ; Koyama, Kaoru</creator><creatorcontrib>Suzuki, Toshinari ; Koyama, Kaoru</creatorcontrib><description>Purpose
The aim of this study was to evaluate the effects of hydroxyethyl starch (HES) 130/0.4/9 compared to 5% albumin on renal and coagulation safety profiles, volume efficacy and glycocalyx degradation in major abdominal surgery.
Methods
The study was approved by the institutional ethics committee as a single center, open-labeled randomized trial. Fifty patients undergoing hepatic or pancreatic surgery were randomly assigned to the HES group (
n
= 25), who received HES 130/0.4/9, or the Albumin group (
n
= 25), who received 5% albumin. Ringer’s acetate solution (3 ml/kg/h) and colloid solution (2 mL/kg/h) were infused and goal-directed fluid management was performed to stabilize hemodynamics. Perioperative changes and differences in serum creatinine, N-acetyl-beta-d-glucosaminidase (NAG), hemodynamics, coagulation parameters and glycocalyx biomarkers were compared between the groups. Blood loss and requirements for transfusion and vasoactive agents were also examined. Statistical analysis was performed by Mann–Whitney
U
tests, chi-square or Fisher exact test, with
P
< 0.05 taken to be significant.
Results
Serum creatinine levels did not differ between the HES and Albumin groups (median: 0.67 vs. 0.75 mg/dL at anesthesia induction, 0.82 vs. 0.83 mg/dL at ICU admission, 0.67 vs. 0.73 mg/dL one day after surgery, 0.68 vs. 0.70 mg/dL one month after surgery). NAG, coagulation parameters, hemodynamics, glycocalyx biomarkers, intraoperative blood loss, transfusion and use of vasoactive agents did not differ between the groups.
Conclusion
HES 130/0.4/9 can be used as safely and effectively as 5% albumin. Glycocalyx degradation did not differ between use of these solutions in major abdominal surgery.</description><identifier>ISSN: 0913-8668</identifier><identifier>EISSN: 1438-8359</identifier><identifier>DOI: 10.1007/s00540-020-02847-y</identifier><identifier>PMID: 32897437</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Albumin ; Albumins ; Anesthesiology ; Comparative analysis ; Critical Care Medicine ; Emergency Medicine ; Fluid Therapy ; Glycocalyx ; Humans ; Hydroxyethyl Starch Derivatives ; Intensive ; Isotonic Solutions ; Medicine ; Medicine & Public Health ; Original Article ; Pain Medicine ; Plasma Substitutes - therapeutic use</subject><ispartof>Journal of anesthesia, 2020-12, Vol.34 (6), p.912-923</ispartof><rights>Japanese Society of Anesthesiologists 2020</rights><rights>COPYRIGHT 2020 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-12f103d557ffc9dfaa6d6bc87971fe49d1fcd1c918c4b4bc71140446689956d33</citedby><cites>FETCH-LOGICAL-c569t-12f103d557ffc9dfaa6d6bc87971fe49d1fcd1c918c4b4bc71140446689956d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00540-020-02847-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00540-020-02847-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32897437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Toshinari</creatorcontrib><creatorcontrib>Koyama, Kaoru</creatorcontrib><title>Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5% albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic and pancreatic surgery</title><title>Journal of anesthesia</title><addtitle>J Anesth</addtitle><addtitle>J Anesth</addtitle><description>Purpose
The aim of this study was to evaluate the effects of hydroxyethyl starch (HES) 130/0.4/9 compared to 5% albumin on renal and coagulation safety profiles, volume efficacy and glycocalyx degradation in major abdominal surgery.
Methods
The study was approved by the institutional ethics committee as a single center, open-labeled randomized trial. Fifty patients undergoing hepatic or pancreatic surgery were randomly assigned to the HES group (
n
= 25), who received HES 130/0.4/9, or the Albumin group (
n
= 25), who received 5% albumin. Ringer’s acetate solution (3 ml/kg/h) and colloid solution (2 mL/kg/h) were infused and goal-directed fluid management was performed to stabilize hemodynamics. Perioperative changes and differences in serum creatinine, N-acetyl-beta-d-glucosaminidase (NAG), hemodynamics, coagulation parameters and glycocalyx biomarkers were compared between the groups. Blood loss and requirements for transfusion and vasoactive agents were also examined. Statistical analysis was performed by Mann–Whitney
U
tests, chi-square or Fisher exact test, with
P
< 0.05 taken to be significant.
Results
Serum creatinine levels did not differ between the HES and Albumin groups (median: 0.67 vs. 0.75 mg/dL at anesthesia induction, 0.82 vs. 0.83 mg/dL at ICU admission, 0.67 vs. 0.73 mg/dL one day after surgery, 0.68 vs. 0.70 mg/dL one month after surgery). NAG, coagulation parameters, hemodynamics, glycocalyx biomarkers, intraoperative blood loss, transfusion and use of vasoactive agents did not differ between the groups.
Conclusion
HES 130/0.4/9 can be used as safely and effectively as 5% albumin. Glycocalyx degradation did not differ between use of these solutions in major abdominal surgery.</description><subject>Albumin</subject><subject>Albumins</subject><subject>Anesthesiology</subject><subject>Comparative analysis</subject><subject>Critical Care Medicine</subject><subject>Emergency Medicine</subject><subject>Fluid Therapy</subject><subject>Glycocalyx</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives</subject><subject>Intensive</subject><subject>Isotonic Solutions</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Plasma Substitutes - therapeutic use</subject><issn>0913-8668</issn><issn>1438-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kl1rHCEUhofS0mzT_oFeFKEEepHZ1dH58DKE9AMCuWmvxdHj7gRHtzoTYn9Zf17cnbRQWIqIHnzeF89HUbwneE0wbjcR45rhEleH3bG2TC-KFWG0Kzta85fFCnNCy65purPiTYz3GOOGEPq6OKNVx1tG21Xx-24PDgXptB-HX6DRFAZpkTdo2gECY0BN8RA2F2iXdPCPCaZdsihOMqgdIhRv8JptOMoWqL5A0vbzODjkHYrSwJTQPngzWLhED97O49F0UFKly6Nka5PyStr0iDRsg9RyGrI2O-xgn-_qSO2lUwGOYZzDFkJ6W7wy0kZ493yeFz8-33y__lre3n35dn11W6q64VNJKkMw1XXdGqO4NlI2uulV1_KWGGBcE6M0UZx0ivWsVy0hDDOWa8Z53WhKz4tPi29O4-cMcRLjEBVYKx34OYqKMcxzCzqS0Y8LupUWxOCMn4JUB1xcNTUhNatwm6nyBLUFB0Fa7-BQq3_59Qk-Lw3joE4KqkWggo8xgBH7MIwyJEGwOAyOWAZH5F-L4-CIlEUfntOc-xH0X8mfSckAXYCYn1zugLj3c3C59P-zfQLYQs4x</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Suzuki, Toshinari</creator><creator>Koyama, Kaoru</creator><general>Springer Singapore</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201201</creationdate><title>Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5% albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic and pancreatic surgery</title><author>Suzuki, Toshinari ; Koyama, Kaoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-12f103d557ffc9dfaa6d6bc87971fe49d1fcd1c918c4b4bc71140446689956d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Albumin</topic><topic>Albumins</topic><topic>Anesthesiology</topic><topic>Comparative analysis</topic><topic>Critical Care Medicine</topic><topic>Emergency Medicine</topic><topic>Fluid Therapy</topic><topic>Glycocalyx</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives</topic><topic>Intensive</topic><topic>Isotonic Solutions</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Plasma Substitutes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Toshinari</creatorcontrib><creatorcontrib>Koyama, Kaoru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Toshinari</au><au>Koyama, Kaoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5% albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic and pancreatic surgery</atitle><jtitle>Journal of anesthesia</jtitle><stitle>J Anesth</stitle><addtitle>J Anesth</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>34</volume><issue>6</issue><spage>912</spage><epage>923</epage><pages>912-923</pages><issn>0913-8668</issn><eissn>1438-8359</eissn><abstract>Purpose
The aim of this study was to evaluate the effects of hydroxyethyl starch (HES) 130/0.4/9 compared to 5% albumin on renal and coagulation safety profiles, volume efficacy and glycocalyx degradation in major abdominal surgery.
Methods
The study was approved by the institutional ethics committee as a single center, open-labeled randomized trial. Fifty patients undergoing hepatic or pancreatic surgery were randomly assigned to the HES group (
n
= 25), who received HES 130/0.4/9, or the Albumin group (
n
= 25), who received 5% albumin. Ringer’s acetate solution (3 ml/kg/h) and colloid solution (2 mL/kg/h) were infused and goal-directed fluid management was performed to stabilize hemodynamics. Perioperative changes and differences in serum creatinine, N-acetyl-beta-d-glucosaminidase (NAG), hemodynamics, coagulation parameters and glycocalyx biomarkers were compared between the groups. Blood loss and requirements for transfusion and vasoactive agents were also examined. Statistical analysis was performed by Mann–Whitney
U
tests, chi-square or Fisher exact test, with
P
< 0.05 taken to be significant.
Results
Serum creatinine levels did not differ between the HES and Albumin groups (median: 0.67 vs. 0.75 mg/dL at anesthesia induction, 0.82 vs. 0.83 mg/dL at ICU admission, 0.67 vs. 0.73 mg/dL one day after surgery, 0.68 vs. 0.70 mg/dL one month after surgery). NAG, coagulation parameters, hemodynamics, glycocalyx biomarkers, intraoperative blood loss, transfusion and use of vasoactive agents did not differ between the groups.
Conclusion
HES 130/0.4/9 can be used as safely and effectively as 5% albumin. Glycocalyx degradation did not differ between use of these solutions in major abdominal surgery.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32897437</pmid><doi>10.1007/s00540-020-02847-y</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0913-8668 |
| ispartof | Journal of anesthesia, 2020-12, Vol.34 (6), p.912-923 |
| issn | 0913-8668 1438-8359 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2440902081 |
| source | MEDLINE; Springer Journals |
| subjects | Albumin Albumins Anesthesiology Comparative analysis Critical Care Medicine Emergency Medicine Fluid Therapy Glycocalyx Humans Hydroxyethyl Starch Derivatives Intensive Isotonic Solutions Medicine Medicine & Public Health Original Article Pain Medicine Plasma Substitutes - therapeutic use |
| title | Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5% albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic and pancreatic surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T17%3A28%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Open%20randomized%20trial%20of%20the%20effects%20of%206%25%20hydroxyethyl%20starch%20130/0.4/9%20and%205%25%20albumin%20on%20safety%20profile,%20volume%20efficacy,%20and%20glycocalyx%20degradation%20in%20hepatic%20and%20pancreatic%20surgery&rft.jtitle=Journal%20of%20anesthesia&rft.au=Suzuki,%20Toshinari&rft.date=2020-12-01&rft.volume=34&rft.issue=6&rft.spage=912&rft.epage=923&rft.pages=912-923&rft.issn=0913-8668&rft.eissn=1438-8359&rft_id=info:doi/10.1007/s00540-020-02847-y&rft_dat=%3Cgale_proqu%3EA651154207%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2440902081&rft_id=info:pmid/32897437&rft_galeid=A651154207&rfr_iscdi=true |